New Stock News | Changchun High-Tech Industry (000661.SZ) is sprinting towards the Hong Kong Stock Exchange, entering the "China Meheco Group Top 100 Industrial Enterprises List" for the eighth consecutive year.

According to the disclosure of the Hong Kong Stock Exchange on September 29th, Changchun High-Tech Industry Technology Industry (Group) Co., Ltd. (referred to as Changchun High-Tech Industry) has submitted its listing application to the main board of the Hong Kong Stock Exchange, with China Securities Co., Ltd. International as its exclusive sponsor. Changchun High-Tech Industry (000661.SZ) is already listed on the Shenzhen Stock Exchange. The prospectus shows that Changchun High-Tech Industry is a leading innovative-driven pharmaceutical group in China, with business covering therapeutic biological products, chemical drugs, vaccines, and traditional Chinese medicine, covering all major types of drug registrations in China. According to data from Frost & Sullivan, the company is one of the few domestic pharmaceutical companies that have achieved research and development, production, and commercialization capabilities across the entire industry chain in the aforementioned types of drugs. With a differentiation innovation strategy as its guide, Changchun High-Tech Industry has formed a competitive and diversified product matrix, not only bringing strong financial performance but also laying a solid foundation for sustainable growth. In 2024, Changchun High-Tech Industry's pharmaceutical product sales revenue reached 12.7 billion RMB, achieving over 10 billion RMB for four consecutive years. Since 2017, Changchun High-Tech Industry has been listed on the "China Meheco Group Top 100 Industrial Enterprises" list for 8 consecutive years. Changchun High-Tech Industry has established a strong and diversified product portfolio in the fields of endocrine and metabolic diseases, women's health, immune and respiratory system diseases, tumors, vaccines, and traditional Chinese medicine. During the historical period and up to September 23, 2025, Changchun High-Tech Industry successfully launched 13 new drug products, such as the herpes zoster vaccine approved in January 2023 (the first and only domestically developed herpes zoster vaccine as of September 23, 2025); injection Firsekibart (Ginsengxin) approved in June 2025 as the first Class 1 innovative biologic drug for acute gouty arthritis in China; Injection Lute Hormone (II) (Jinsaixin) approved in June 2024 (China's first subcutaneous soluble lutein hormone injection included in the 2024 National Medical Insurance Drug List), and liquid nasal spray influenza vaccine approved in August 2025. Changchun High-Tech Industry is also actively expanding the indications coverage of approved products to target a wider range of patient populations. For example, Jinsai was approved for use in ISS and Turner syndrome in 2024, becoming the only LAGH product approved for indications outside of PGHD in China, covering approximately 82.3% of the children's dwarf population in China. As of September 23, 2025, Changchun High-Tech Industry has over 40 clinical stage or candidate drugs that have been submitted for new drug clinical trials (IND), including 14 Phase III clinical stage or new drug application (NDA) candidates and 15 Class 1 innovative drugs. Several candidate drugs demonstrate global first-mover or best-in-class potential. In terms of performance, in the fiscal years 2022, 2023, 2024, and the six months ending June 30, 2025, the company achieved revenues of approximately 12.627 billion, 14.566 billion, 13.466 billion, and 6.603 billion RMB, respectively; during the same period, annual/periodic profits were approximately 4.215 billion, 4.776 billion, 2.708 billion, and 930 million RMB.